|
Aug 9
|
Xencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
|
|
Aug 8
|
Xencor price target lowered to $26 from $31 at Wedbush
|
|
Aug 6
|
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 6
|
Xencor: Q2 Earnings Snapshot
|
|
Aug 6
|
Xencor Reports Second Quarter 2025 Financial Results
|
|
Jul 31
|
Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
|
|
Jul 31
|
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
|
|
Mar 13
|
Xencor Appoints Todd Simpson to Board of Directors
|
|
Feb 28
|
Xencor Full Year 2024 Earnings: Beats Expectations
|
|
Feb 27
|
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Xencor: Q4 Earnings Snapshot
|
|
Feb 27
|
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Nov 14
|
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
|
|
Nov 12
|
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14%
|
|
Oct 10
|
Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
|
|
Jun 22
|
Xencor (NASDAQ:XNCR) shareholders have endured a 52% loss from investing in the stock five years ago
|
|
Jun 13
|
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
|
|
May 11
|
Xencor First Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Xencor Inc (XNCR) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
|
|
May 9
|
Xencor Reports First Quarter 2024 Financial Results
|